Report
EUR 200.00
For Business Accounts Only
The company will unveil the full results of the phase III EMA and phase 2b FDA studies on AMBAR (~8% of our € 30.50/sh. T.P.) for Alzheimer at San Diego’s CTAD Congress (US). These results will be relevant, as in addition to further information it could dispel doubts on the commercial strategy (presentation of the study to the EMA/FDA and/or search of off-label use). According to our estimates, the stock is pricing in ~30% chances of success vs. 20% in our case, and thus in order to see >15% upside we should assign ~60% chances of success and necessary data will be necessary to confirm/improve the efficacy levels and greater evidence through neuroimaging and biomarkers.
GRIFOLS: MOMENT OF TRUTH FOR AMBAR (ANÃLISIS BANCO SABADELL)
The moment of truth for AMBAR. SELL.The company will unveil the full results of the phase III EMA and phase 2b FDA studies on AMBAR (~8% of our € 30.50/sh. T.P.) for Alzheimer at San Diego’s CTAD Congress (US). These results will be relevant, as in addition to further information it could dispel doubts on the commercial strategy (presentation of the study to the EMA/FDA and/or search of off-label use). According to our estimates, the stock is pricing in ~30% chances of success vs. 20% in our case, and thus in order to see >15% upside we should assign ~60% chances of success and necessary data will be necessary to confirm/improve the efficacy levels and greater evidence through neuroimaging and biomarkers.
Underlying
Grifols (GRF SM)
Provider
Sabadell
Luis Arredondo
Other Reports on these Companies
Other Reports from Sabadell
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.